IP Verse

Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or Agonist - EP2144613

The patent EP2144613 was granted to Ossifi MAB on Mar 21, 2018. The application was originally filed on Dec 21, 2007 under application number EP07875255A. The patent is currently recorded with a legal status of "Revoked".

EP2144613

OSSIFI MAB
Application Number
EP07875255A
Filing Date
Dec 21, 2007
Status
Revoked
Dec 8, 2023
Grant Date
Mar 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

UCB BIOPHARMADec 21, 2018J A KEMPADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2007292444
INTERNATIONAL-SEARCH-REPORTWO03039534
INTERNATIONAL-SEARCH-REPORTWO03073991
INTERNATIONAL-SEARCH-REPORTWO03106657
INTERNATIONAL-SEARCH-REPORTWO2005003158
INTERNATIONAL-SEARCH-REPORTWO2006102070
INTERNATIONAL-SEARCH-REPORTWO2006119107
INTERNATIONAL-SEARCH-REPORTWO2008133722
OPPOSITIONUS2004002770
OPPOSITIONUS2004023356
OPPOSITIONUS2007292444
OPPOSITIONWO2006119107

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- DIEZ, "Skeletal effects of selective oestrogen receptor modulators (SERMs)", Human Reproduction Update, (20000000), vol. 6, no. 3, pages 255 - 258, XP002570654-
OPPOSITION- KHOSLA et al., "Concise review for primary-care physicians (Treatment options for osteoporous)", Mayo Clin Proc, (19950000), vol. 70, pages 978 - 982, XP055566009-
OPPOSITION- GIANNOUDIS et al., "Bone substitutes: An update", Injury, Int. J. Care Injured, (20050000), pages S20 - S27, XP005091504
OPPOSITION- LI et al., "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling", J. Biol. Chem., (20050000), vol. 280, pages 19883 - 19887, XP002391780
OPPOSITION- ELLIES et al., "Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity", J Bone Miner Res, (20060000), vol. 21, pages 1738 - 1749, XP002554008
OPPOSITION- LEWIECKI, "RANK ligand inhibition with denosumab for the management of osteoporosis", Expert Opin. Biol. Ther., (20060000), vol. 6, no. 10, pages 1041 - 1050, XP009126652
OPPOSITION- LAURENCIN et al., "Bone graft substitutes", Expert Rev. Med. Devices, (20060000), vol. 3, no. 1, pages 49 - 57, XP055565987
OPPOSITION- LIM et al., "Drug Design", Development and Therapy, (20170000), vol. 11, pages 1221 - 1231, XP055566021

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents